← Revolution Medicines overview

Revolution Medicines vs Vertex Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Revolution Medicines Inc (RVMD)

Q3 2026
▲3▼1

FDA approval turns Revolution Medicines into commercial-stage company

  • Daraxonrasib Phase 3 survival win Strong Phase 3 data for daraxonrasib in metastatic pancreatic cancer nearly doubled median overall survival, a major clinical win that supports a roughly $40 billion valuation and validates the company's RAS-targeted approach.

    This was the key clinical catalyst that re-rated the stock during the quarter.

  • FDA approval of Rasonque In September the FDA approved daraxonrasib (Rasonque), the first RAS-targeted pancreatic cancer drug, making Revolution Medicines a commercial-stage company with real revenue potential and a first-mover position.

    The approval is the single biggest new event, changing the company's business model.

  • Regulatory designations and funding Breakthrough Therapy and Orphan Drug designations, EMA accelerated review, and a Royalty Pharma deal fund the pipeline without dilution, while Parnassus Growth Equity initiated a position, signaling institutional confidence.

    These developments de-risk the launch and strengthen the balance sheet without shareholder dilution.

  • Cost and pricing concerns A wider-than-expected Q2 loss and raised 2026 spending guidance (second time) cast doubt on profitability timing, while Rasonque's $39,800 monthly price raises insurer coverage and patient affordability concerns that could limit sales.

    This is the main counterweight, showing the commercial path is not without financial and access risks.

September 2026
▲3

FDA approval turns Revolution Medicines into a commercial cancer drugmaker

  • FDA approves first RAS-targeted pancreatic cancer drug The FDA approved daraxonrasib, sold as Rasonque, for previously treated metastatic pancreatic cancer. It is the first targeted pill for this hard-to-treat disease, nearly doubling median survival versus chemotherapy. This turns a clinical-stage company into one with an approved product and real revenue potential, lifting the stock.

    This is the single biggest new event of the period and the core reason RVMD is moving.

  • Price set at $39,800 per month Revolution priced Rasonque at $39,800 for a 30-day supply, about $477,600 a year before discounts. That is high enough to raise concerns about whether insurers will cover it and whether patients can afford it, which could limit sales even though the price itself supports revenue per patient.

    Pricing is the main commercial counterweight to the approval and directly affects how much revenue the drug can generate.

  • Royalty Pharma deal funds pipeline without dilution A new partnership with Royalty Pharma provides funding for Revolution's pipeline without selling more shares. That matters because the company had no revenue in FY2025 and lost about $1.1 billion, so this eases the need for cash and protects existing shareholders from dilution.

    It answers how the company pays for its pipeline now that it has a product but still spends heavily.

  • Fund manager cites drug as potential new standard of care Parnassus Growth Equity Fund added Revolution Medicines as a new holding, saying daraxonrasib's late-stage results suggest it could become a standard treatment for pancreatic cancer with significant commercial potential. A respected fund buying in signals growing institutional confidence, which can support the stock.

    It shows professional investors are treating the approval as a durable long-term opportunity, not just a one-day event.

Latest
▲3

FDA approval turns Revolution Medicines into a commercial cancer drugmaker

  • FDA approves first RAS-targeted pancreatic cancer drug The FDA approved daraxonrasib, sold as Rasonque, for previously treated metastatic pancreatic cancer. It is the first targeted pill for this hard-to-treat disease, nearly doubling median survival versus chemotherapy. This turns a clinical-stage company into one with an approved product and real revenue potential, lifting the stock.

    This is the single biggest new event of the period and the core reason RVMD is moving.

  • Price set at $39,800 per month Revolution priced Rasonque at $39,800 for a 30-day supply, about $477,600 a year before discounts. That is high enough to raise concerns about whether insurers will cover it and whether patients can afford it, which could limit sales even though the price itself supports revenue per patient.

    Pricing is the main commercial counterweight to the approval and directly affects how much revenue the drug can generate.

  • Royalty Pharma deal funds pipeline without dilution A new partnership with Royalty Pharma provides funding for Revolution's pipeline without selling more shares. That matters because the company had no revenue in FY2025 and lost about $1.1 billion, so this eases the need for cash and protects existing shareholders from dilution.

    It answers how the company pays for its pipeline now that it has a product but still spends heavily.

  • Fund manager cites drug as potential new standard of care Parnassus Growth Equity Fund added Revolution Medicines as a new holding, saying daraxonrasib's late-stage results suggest it could become a standard treatment for pancreatic cancer with significant commercial potential. A respected fund buying in signals growing institutional confidence, which can support the stock.

    It shows professional investors are treating the approval as a durable long-term opportunity, not just a one-day event.

July 2026
▲3▼1

RVMD Soars on Strong Phase 3 Data, Regulatory Wins, and Competitive Edge

  • Daraxonrasib Phase 3 Data Revolution Medicines reported strong Phase 3 results for daraxonrasib in metastatic pancreatic cancer, with median overall survival nearly doubling to 13.2 months from 6.7 months, supporting a ~$40B valuation and a $10B+ market opportunity.

    This is the primary positive catalyst that drove the stock's surge during the period.

  • Regulatory Designations and NDA Acceptance The company received Breakthrough Therapy and Orphan Drug designations, EMA accelerated review, and FDA acceptance of the daraxonrasib NDA with a fast-review voucher, building regulatory momentum.

    These regulatory milestones accelerate the path to market and boost investor confidence.

  • Competitor Erasca Legal Woes Erasca faces securities litigation and investigations over alleged misleading comparisons to RVMD's RMC-6236, erasing $2.8B in market cap, which strengthens RVMD's competitive position.

    This weakens a rival and reinforces RVMD's leadership in the RAS cancer space.

  • Wider Q2 Loss and Raised Spending Guidance RVMD reported a wider-than-expected Q2 loss and raised 2026 spending guidance for the second time, raising doubts about how soon the company can reach profitability.

    This is a counterweight that could pressure the stock despite positive pipeline news.

▲3▼1

FDA accepts daraxonrasib NDA, but rising costs test RVMD's valuation

  • FDA accepts daraxonrasib NDA The FDA accepted Revolution Medicines' application for daraxonrasib in metastatic pancreatic cancer, a key step toward approval. The drug also got a fast-review voucher. This raises the chance of a launch and future sales, supporting the stock.

    This is the period's biggest new regulatory event and directly drives RVMD's potential revenue.

  • Druckenmiller's fund buys RVMD shares Billionaire Stanley Druckenmiller's family office bought 316,000 shares. A well-known investor buying in can boost confidence and attract other buyers, pushing the stock up. It also highlights the drug's strong survival data.

    This is a new, specific event that can influence investor sentiment and demand for the stock.

  • Wider Q2 loss and higher expense guidance Revolution Medicines reported a bigger quarterly loss than expected and raised its 2026 spending forecast for the second time. Costs are climbing fast as it prepares for launch. This raises doubts about how soon it can become profitable, weighing on the stock.

    This is the main new negative financial update and a real counterweight to the positive news.

  • Erasca legal probe continues Hagens Berman is investigating Erasca over alleged misleading claims about its drug, including flawed comparisons to RVMD's RMC-6236. This keeps pressure on a competitor and reinforces RVMD's competitive edge in RAS cancer drugs.

    It is a new development in a competitive threat that benefits RVMD's relative position.

▲4

Revolution Medicines' cancer data and regulatory wins drive RVMD higher

  • Daraxonrasib Phase 3 survival data and $40B valuation Daraxonrasib nearly doubled median overall survival (13.2 vs 6.7 months) in previously treated metastatic pancreatic cancer, supporting a potential $10B+ opportunity and a ~$40B market value. This validates the pipeline and raises expectations for future revenue.

    This is the core clinical catalyst that justifies RVMD's valuation and future revenue potential.

  • Zoldonrasib combination shows high response rates Phase 1/2 data for zoldonrasib plus chemo in RAS G12D pancreatic cancer showed 82% and 61% response rates in untreated patients, and 50% in previously treated patients. These results support ongoing Phase 3 trials and expand the pipeline's potential.

    New positive data for a second drug candidate broadens the growth story and de-risks the pipeline.

  • Regulatory progress: Breakthrough Therapy, Orphan Drug, EMA accelerated review Daraxonrasib received Breakthrough Therapy and Orphan Drug designations, and the European Medicines Agency launched an accelerated review. The company is nearing completion of its New Drug Application to the FDA, setting the stage for a potential global launch.

    Regulatory milestones shorten the path to market and increase the probability of approval, directly impacting future sales.

  • Erasca legal troubles weaken a competitor Erasca faces a securities class action over alleged improper comparisons to RVMD's RMC-6236 and a patient death, erasing $2.8B in market cap. This strengthens RVMD's competitive position and intellectual property standing in the RAS cancer space.

    A weakened competitor reduces competitive pressure and reinforces RVMD's leadership, supporting its pricing power and market share.

Q2 2026
▲3

Revolution Medicines advances pancreatic cancer pipeline as rival Erasca faces legal fallout

  • Phase 3 trial launch for zoldonrasib Revolution Medicines began treating patients in RASolute 305, a Phase 3 trial of zoldonrasib plus chemotherapy for first-line metastatic pancreatic cancer. This is a key step toward a potential new drug, boosting investor confidence in the company's pipeline and future revenue.

    This is a major clinical milestone that directly advances RVMD's lead drug and could drive long-term value.

  • Upcoming data presentations at ESMO GI 2026 Revolution Medicines will present clinical data from its RAS(ON) inhibitor pipeline at the ESMO GI 2026 congress, including oral reports on zoldonrasib combinations and updates on two Phase 3 trials. Positive data could further validate the pipeline and attract investor interest.

    Upcoming data readouts are near-term catalysts that can influence RVMD's stock price.

  • Competitive edge from Erasca patent dispute Revolution Medicines accused rival Erasca of patent infringement and trade secret misappropriation over ERAS-0015, leading to a securities class action against Erasca. This weakens a competitor and reinforces RVMD's intellectual property position in the RAS cancer space.

    The legal challenge against Erasca strengthens RVMD's competitive standing and removes a potential rival.

June 2026
▲3

Revolution Medicines advances pancreatic cancer pipeline as rival Erasca faces legal fallout

  • Phase 3 trial launch for zoldonrasib Revolution Medicines began treating patients in RASolute 305, a Phase 3 trial of zoldonrasib plus chemotherapy for first-line metastatic pancreatic cancer. This is a key step toward a potential new drug, boosting investor confidence in the company's pipeline and future revenue.

    This is a major clinical milestone that directly advances RVMD's lead drug and could drive long-term value.

  • Upcoming data presentations at ESMO GI 2026 Revolution Medicines will present clinical data from its RAS(ON) inhibitor pipeline at the ESMO GI 2026 congress, including oral reports on zoldonrasib combinations and updates on two Phase 3 trials. Positive data could further validate the pipeline and attract investor interest.

    Upcoming data readouts are near-term catalysts that can influence RVMD's stock price.

  • Competitive edge from Erasca patent dispute Revolution Medicines accused rival Erasca of patent infringement and trade secret misappropriation over ERAS-0015, leading to a securities class action against Erasca. This weakens a competitor and reinforces RVMD's intellectual property position in the RAS cancer space.

    The legal challenge against Erasca strengthens RVMD's competitive standing and removes a potential rival.

▲3

Revolution Medicines advances pancreatic cancer pipeline as rival Erasca faces legal fallout

  • Phase 3 trial launch for zoldonrasib Revolution Medicines began treating patients in RASolute 305, a Phase 3 trial of zoldonrasib plus chemotherapy for first-line metastatic pancreatic cancer. This is a key step toward a potential new drug, boosting investor confidence in the company's pipeline and future revenue.

    This is a major clinical milestone that directly advances RVMD's lead drug and could drive long-term value.

  • Upcoming data presentations at ESMO GI 2026 Revolution Medicines will present clinical data from its RAS(ON) inhibitor pipeline at the ESMO GI 2026 congress, including oral reports on zoldonrasib combinations and updates on two Phase 3 trials. Positive data could further validate the pipeline and attract investor interest.

    Upcoming data readouts are near-term catalysts that can influence RVMD's stock price.

  • Competitive edge from Erasca patent dispute Revolution Medicines accused rival Erasca of patent infringement and trade secret misappropriation over ERAS-0015, leading to a securities class action against Erasca. This weakens a competitor and reinforces RVMD's intellectual property position in the RAS cancer space.

    The legal challenge against Erasca strengthens RVMD's competitive standing and removes a potential rival.

Vertex Pharmaceuticals Inc (VRTX)

Q3 2026
▲3▼1

Vertex beats Q2, buys Crinetics, but faces competition and premium valuation

  • Strong Q2 results and buyback Vertex reported Q2 revenue up 12% to $3.3 billion, raised full-year guidance, and announced a $1.42 billion share buyback. This shows the core business is performing well and returning cash to shareholders.

    This is new financial information that directly reflects the company's current performance and capital return.

  • Crinetics acquisition adds diversification Vertex completed the $10 billion acquisition of Crinetics Pharmaceuticals, adding up to $5 billion in peak annual sales and diversifying beyond cystic fibrosis. The deal is expected to boost revenue immediately and contribute to operating profit by 2029.

    This is a major strategic move that expands Vertex's product portfolio and long-term growth prospects.

  • Pipeline and regulatory wins Casgevy's pediatric expansion, positive inaxaplin kidney data, and a rival CF drug failure strengthen Vertex's outlook. Morgan Stanley initiated coverage with an Overweight rating and a $665 price target.

    These events improve the company's competitive position and future revenue potential.

  • Competition and valuation risks Novartis' Fabhalta is already approved in IgA nephropathy, threatening Vertex's povetacicept (FDA decision due Nov 30, 2026). The Crinetics deal carried a roughly 100% premium, and Vertex trades at a premium valuation with slipping 2026 earnings estimates.

    These are real counterweights that could pressure the stock if execution falters.

August 2026
▲3▼1

Vertex gains on rival CF failure, buyback, and pipeline wins

  • Rival CF drug failure removes competitive threat Sionna's CF drug failure eliminated a potential competitor, strengthening Vertex's dominant position in cystic fibrosis and boosting investor confidence.

    This is a new competitive development that directly benefits Vertex's core franchise.

  • Q2 beat, raised guidance, and $1.42B buyback Vertex reported Q2 revenue of $3.33B (up 12.5%), raised 2026 guidance to $13.1–13.2B, and announced a $1.42B buyback, signaling strong financial health.

    These are new financial updates that directly support the stock price.

  • Non-CF drugs gain traction; pipeline advances Journavx and Casgevy are gaining traction, with non-CF revenue expected to exceed $500M in 2026. Inaxaplin's positive Phase 2 kidney data validated its mechanism, and ALYFTREK advanced in Canada.

    These new pipeline and commercial updates show diversification and future growth potential.

  • Competition and valuation risks persist Novartis' Fabhalta is already approved in IgA nephropathy, posing a threat to Vertex's povetacicept. Vertex trades at a premium valuation, and 2026 earnings estimates have slipped.

    This counterweight highlights ongoing risks that could pressure the stock.

Latest
▲4

Vertex's $10B Crinetics Deal, Kidney Data and ALYFTREK Win Drive Upside

  • Crinetics acquisition adds new endocrine franchise Vertex agreed to buy Crinetics for about $10 billion, adding an approved acromegaly drug and a late-stage hormone disorder treatment. The deal opens a new treatment area beyond cystic fibrosis and is expected to add to operating income by 2029, supporting a higher stock price.

    This is the period's biggest strategic move, diversifying Vertex beyond CF and adding a new growth engine.

  • CASGEVY expanded to young children; ALYFTREK advances in Canada The FDA widened CASGEVY's approval to children as young as 2, growing the number of patients who can get the one-time gene therapy. Vertex also signed a Canadian access deal for ALYFTREK, its next-generation CF drug, moving it toward public reimbursement for about 3,800 patients.

    These regulatory and access wins broaden the patient base for two key products, lifting future sales potential.

  • ALYFTREK restores pancreatic function in young CF children New interim data showed ALYFTREK restored pancreatic function in some children ages 2 to 5 with cystic fibrosis, letting many stop enzyme replacement therapy. This suggests treating CF earlier can reverse damage once thought permanent, strengthening ALYFTREK's long-term role and pricing power.

    This clinical win reinforces Vertex's core CF franchise and could expand ALYFTREK's use and pricing.

  • Kidney drug data validates APOL1 mechanism, but competition looms Positive Phase 2 data for inaxaplin in a kidney disease validated the approach and pointed to a market of over 100,000 patients. However, rivals like Novartis' Fabhalta are already approved, so Vertex must execute well to capture share and justify its pipeline value.

    This confirms a new kidney franchise but also flags real competition that could cap upside.

September 2026
▲3

Vertex's $10B Crinetics Buy and Kidney Pipeline Progress Drive Upside

  • Crinetics acquisition diversifies beyond CF Vertex completed its $10 billion purchase of Crinetics, adding Palsonify (approved for acromegaly) and atumelnant (late-stage for a hormone disorder). This opens a new treatment area beyond cystic fibrosis, supporting long-term growth and a higher stock price.

    This is the period's biggest new event, directly expanding Vertex's business and analyst price targets.

  • Morgan Stanley starts with Overweight and $665 target Morgan Stanley resumed coverage with an Overweight rating and a $665 price target, citing the Crinetics deal's diversification. The analyst raised Vertex's long-term revenue growth estimate to 13.8% from 12.1%, which helps justify a higher valuation.

    A major analyst upgrade directly influences investor sentiment and price targets.

  • Positive kidney drug data and FDA filing progress Vertex reported positive Phase IIb data for inaxaplin in a kidney disease, showing large reductions in protein in urine, and completed enrollment in a pivotal study. The FDA also accepted its filing for povetacicept, with a decision due Nov. 30, 2026. These advance a new kidney franchise.

    New clinical and regulatory progress adds a potential multi-billion-dollar revenue stream beyond CF.

  • Competition in kidney disease and high deal premium Vertex's kidney pipeline faces competition: Novartis' Fabhalta and other drugs are already approved for IgA nephropathy. Also, Vertex paid a roughly 100% premium for Crinetics, raising the bar for success. These factors could limit upside if execution disappoints.

    Provides a fair counterweight to the positive news, highlighting real risks.

▲3

Vertex's $10B Crinetics Buy and Kidney Pipeline Progress Drive Upside

  • Crinetics acquisition diversifies beyond CF Vertex completed its $10 billion purchase of Crinetics, adding Palsonify (approved for acromegaly) and atumelnant (late-stage for a hormone disorder). This opens a new treatment area beyond cystic fibrosis, supporting long-term growth and a higher stock price.

    This is the period's biggest new event, directly expanding Vertex's business and analyst price targets.

  • Morgan Stanley starts with Overweight and $665 target Morgan Stanley resumed coverage with an Overweight rating and a $665 price target, citing the Crinetics deal's diversification. The analyst raised Vertex's long-term revenue growth estimate to 13.8% from 12.1%, which helps justify a higher valuation.

    A major analyst upgrade directly influences investor sentiment and price targets.

  • Positive kidney drug data and FDA filing progress Vertex reported positive Phase IIb data for inaxaplin in a kidney disease, showing large reductions in protein in urine, and completed enrollment in a pivotal study. The FDA also accepted its filing for povetacicept, with a decision due Nov. 30, 2026. These advance a new kidney franchise.

    New clinical and regulatory progress adds a potential multi-billion-dollar revenue stream beyond CF.

  • Competition in kidney disease and high deal premium Vertex's kidney pipeline faces competition: Novartis' Fabhalta and other drugs are already approved for IgA nephropathy. Also, Vertex paid a roughly 100% premium for Crinetics, raising the bar for success. These factors could limit upside if execution disappoints.

    Provides a fair counterweight to the positive news, highlighting real risks.

▲3

Vertex Rises as Rival CF Drug Fails and Guidance Climbs

  • Rival CF drug failure clears competitive threat Sionna's SION-719 failed its Phase 2a trial, and the company dropped the program. That removes a would-be competitor to Vertex's cystic fibrosis franchise, which brings in most of its revenue. Less competition means Vertex can keep its dominant share and pricing power, pushing the stock up.

    This is the biggest new event of the period and directly lifts Vertex's core CF business.

  • Q2 revenue beat and raised 2026 guidance Vertex reported Q2 revenue of $3.33 billion, up 12.5% and above estimates, and raised full-year revenue guidance to $13.1–$13.2 billion. It also completed a $1.42 billion share buyback. Strong sales and a brighter outlook support a higher stock price.

    The quarter's results and guidance are the core financial driver behind the stock's move.

  • Non-CF products gaining traction Newer non-CF drugs Journavx and Casgevy posted combined Q2 sales of $126 million, and Vertex expects non-CF revenue to top $500 million in 2026, up about 185%. This shows the company is building growth beyond cystic fibrosis, which supports a higher valuation.

    It shows the post-CF growth story is real, a key reason investors are paying up for the stock.

  • Kidney competition and valuation keep a lid on gains Novartis' Fabhalta is already fully approved for IgA nephropathy, while Vertex's povetacicept faces an FDA decision by Nov. 30, 2026. Vertex also trades at a premium to peers, and 2026 earnings estimates have slipped. These are real counterweights that could limit upside.

    It gives the fair counterweight: competition and a rich valuation could cap further gains.

July 2026
▲3▼1

Vertex's Q2 beat and Crinetics deal drive growth, but kidney competition looms

  • Q2 revenue surges 12% to $3.3B, guidance raised Vertex reported Q2 revenue of $3.3 billion, up 12% year-over-year, driven by CF and newer products. Full-year guidance was raised to $13.1–13.2 billion, and EPS beat expectations. This strong financial performance supports a higher stock price by showing robust demand and execution.

    This is the most recent and direct positive financial update, showing accelerating growth and raised outlook.

  • Crinetics acquisition adds $5B peak sales potential Vertex agreed to acquire Crinetics for $10 billion, gaining paltusotine (PALSONIFY) and atumelnant. The deal is expected to add up to $5 billion in peak revenue and diversify beyond CF. While it uses cash, the strategic fit and growth potential outweigh the cost.

    This is a major strategic move that expands Vertex's rare disease portfolio and long-term growth prospects.

  • Novartis' Fabhalta full approval intensifies kidney competition The FDA granted full approval to Novartis' Fabhalta for IgA nephropathy, a direct competitor to Vertex's povetacicept (target action date Nov 30, 2026). This could limit povetacicept's market share and pricing power, posing a risk to Vertex's kidney pipeline.

    This is a new competitive threat that could impact a key growth driver for Vertex.

  • Casgevy approval expanded to children as young as 2 The FDA expanded Casgevy's approval to treat children aged 2 and older with sickle cell disease or thalassemia. This broadens the eligible patient population and strengthens Vertex's gene therapy franchise, though real-world uptake and reimbursement will determine the actual revenue impact.

    This regulatory win opens a new pediatric market for Casgevy, supporting long-term growth.

▲3▼1

Vertex's Q2 beat and Crinetics deal drive growth, but kidney competition looms

  • Q2 revenue surges 12% to $3.3B, guidance raised Vertex reported Q2 revenue of $3.3 billion, up 12% year-over-year, driven by CF and newer products. Full-year guidance was raised to $13.1–13.2 billion, and EPS beat expectations. This strong financial performance supports a higher stock price by showing robust demand and execution.

    This is the most recent and direct positive financial update, showing accelerating growth and raised outlook.

  • Crinetics acquisition adds $5B peak sales potential Vertex agreed to acquire Crinetics for $10 billion, gaining paltusotine (PALSONIFY) and atumelnant. The deal is expected to add up to $5 billion in peak revenue and diversify beyond CF. While it uses cash, the strategic fit and growth potential outweigh the cost.

    This is a major strategic move that expands Vertex's rare disease portfolio and long-term growth prospects.

  • Novartis' Fabhalta full approval intensifies kidney competition The FDA granted full approval to Novartis' Fabhalta for IgA nephropathy, a direct competitor to Vertex's povetacicept (target action date Nov 30, 2026). This could limit povetacicept's market share and pricing power, posing a risk to Vertex's kidney pipeline.

    This is a new competitive threat that could impact a key growth driver for Vertex.

  • Casgevy approval expanded to children as young as 2 The FDA expanded Casgevy's approval to treat children aged 2 and older with sickle cell disease or thalassemia. This broadens the eligible patient population and strengthens Vertex's gene therapy franchise, though real-world uptake and reimbursement will determine the actual revenue impact.

    This regulatory win opens a new pediatric market for Casgevy, supporting long-term growth.

Q2 2026
▲4

Vertex expands kidney, gene therapy, and rare disease reach

  • Kidney pipeline could add billions Vertex's kidney disease pipeline, including povetacicept and inaxaplin, is seen as a multi-billion-dollar growth driver. Positive late-stage data and a rolling FDA submission for povetacicept could diversify revenue beyond cystic fibrosis, lifting long-term sales expectations.

    This is a new growth opportunity that expands Vertex's revenue base and supports a higher valuation.

  • Casgevy approved for young children The FDA approved Casgevy for children as young as 2, expanding the market by about 5,500 U.S. patients and a $12.1 billion commercial opportunity. This regulatory win boosts Vertex's gene therapy revenue potential and strengthens its diversification story.

    A major regulatory expansion directly increases the addressable market and future sales for a key Vertex product.

  • Vertex to buy Crinetics for $10 billion Vertex agreed to acquire Crinetics Pharmaceuticals for about $10 billion, adding the acromegaly drug paltusotine and other assets. The deal is expected to immediately boost revenue and contribute to operating profit by 2029, with over $5 billion in peak annual revenue potential.

    This large acquisition expands Vertex's rare disease portfolio and provides near-term revenue growth, a key driver of the stock.

  • ALYFTREK gains Canadian reimbursement Vertex signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, making about 3,800 cystic fibrosis patients in Canada eligible. This expands access to Vertex's newest CF therapy, supporting incremental revenue growth in a core franchise.

    New reimbursement expands the market for a key cystic fibrosis product, directly supporting Vertex's revenue.

June 2026
▲4

Vertex expands kidney, gene therapy, and rare disease reach

  • Kidney pipeline could add billions Vertex's kidney disease pipeline, including povetacicept and inaxaplin, is seen as a multi-billion-dollar growth driver. Positive late-stage data and a rolling FDA submission for povetacicept could diversify revenue beyond cystic fibrosis, lifting long-term sales expectations.

    This is a new growth opportunity that expands Vertex's revenue base and supports a higher valuation.

  • Casgevy approved for young children The FDA approved Casgevy for children as young as 2, expanding the market by about 5,500 U.S. patients and a $12.1 billion commercial opportunity. This regulatory win boosts Vertex's gene therapy revenue potential and strengthens its diversification story.

    A major regulatory expansion directly increases the addressable market and future sales for a key Vertex product.

  • Vertex to buy Crinetics for $10 billion Vertex agreed to acquire Crinetics Pharmaceuticals for about $10 billion, adding the acromegaly drug paltusotine and other assets. The deal is expected to immediately boost revenue and contribute to operating profit by 2029, with over $5 billion in peak annual revenue potential.

    This large acquisition expands Vertex's rare disease portfolio and provides near-term revenue growth, a key driver of the stock.

  • ALYFTREK gains Canadian reimbursement Vertex signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, making about 3,800 cystic fibrosis patients in Canada eligible. This expands access to Vertex's newest CF therapy, supporting incremental revenue growth in a core franchise.

    New reimbursement expands the market for a key cystic fibrosis product, directly supporting Vertex's revenue.

▲4

Vertex expands kidney, gene therapy, and rare disease reach

  • Kidney pipeline could add billions Vertex's kidney disease pipeline, including povetacicept and inaxaplin, is seen as a multi-billion-dollar growth driver. Positive late-stage data and a rolling FDA submission for povetacicept could diversify revenue beyond cystic fibrosis, lifting long-term sales expectations.

    This is a new growth opportunity that expands Vertex's revenue base and supports a higher valuation.

  • Casgevy approved for young children The FDA approved Casgevy for children as young as 2, expanding the market by about 5,500 U.S. patients and a $12.1 billion commercial opportunity. This regulatory win boosts Vertex's gene therapy revenue potential and strengthens its diversification story.

    A major regulatory expansion directly increases the addressable market and future sales for a key Vertex product.

  • Vertex to buy Crinetics for $10 billion Vertex agreed to acquire Crinetics Pharmaceuticals for about $10 billion, adding the acromegaly drug paltusotine and other assets. The deal is expected to immediately boost revenue and contribute to operating profit by 2029, with over $5 billion in peak annual revenue potential.

    This large acquisition expands Vertex's rare disease portfolio and provides near-term revenue growth, a key driver of the stock.

  • ALYFTREK gains Canadian reimbursement Vertex signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, making about 3,800 cystic fibrosis patients in Canada eligible. This expands access to Vertex's newest CF therapy, supporting incremental revenue growth in a core franchise.

    New reimbursement expands the market for a key cystic fibrosis product, directly supporting Vertex's revenue.